Shares of Novo Nordisk A/S (NVO.US) rose 6% on Monday, trading at $45.79.

The increase follows a recent statement from the company's CEO clarifying that the regulatory data protection period for its blockbuster drug semaglutide in China will now last until April 2027. This date extends the market exclusivity by over a year beyond the core compound patent's expiration in March 2026.

Estimates suggest this additional 13-month protection period is expected to generate approximately $1 billion in stable, incremental cash flow for the pharmaceutical firm.